Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients
Overview
- Phase
- Phase 4
- Intervention
- Denosumab treatment in osteoporotic patients
- Conditions
- Osteoporosis
- Sponsor
- Shinshu University
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Changes of bone mineral density
- Last Updated
- 5 years ago
Overview
Brief Summary
It has not been well known about the changes of bone metabolic markers, bone mineral density and other bone-related markers after teriparatide and/or denosumab treatment in Japanese osteoporotic patients.
Investigators
Yukio Nakamura
Assistant Professor
Shinshu University
Eligibility Criteria
Inclusion Criteria
- •Osteoporotic patients
Exclusion Criteria
- Not provided
Arms & Interventions
Denosumab and/or teriparatide treatment
Denosumab and/or teriparatide treatment in osteoporotic patients
Intervention: Denosumab treatment in osteoporotic patients
Denosumab and/or teriparatide treatment
Denosumab and/or teriparatide treatment in osteoporotic patients
Intervention: Teriparatide treatment in osteoporotic patients
Denosumab and/or teriparatide treatment
Denosumab and/or teriparatide treatment in osteoporotic patients
Intervention: Denosumab and teriparatide treatment in osteoporotic patients
Outcomes
Primary Outcomes
Changes of bone mineral density
Time Frame: every 4-6 months
Bone mineral density will be examined every 4-6 months to evaluate the suitability of the drug.
Secondary Outcomes
- Changes of bone turnover markers(every 3-6 months)